Mito Prime

Blend

ClassEnergy / metabolic three-component blend

Typical routes in papersSC in community citations

Half-life contextPer component

EvidenceEach ingredient has its own papers; the 120 mg vial does not

What it is

Mito Prime (MitoPrime) is a shop blend, usually NAD+ 100 mg + MOTS-c 10 mg + 5-Amino-1MQ 10 mg (120 mg). Only MOTS-c is a true peptide. NAD+ is a coenzyme. 5-Amino-1MQ is a small-molecule NNMT blocker already in this library as its own page.

Benefits in plain language

What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.

What people want: cellular energy (NAD+), exercise-mimetic metabolic signaling (MOTS-c), and a fat-cell NAD-sparing angle (5-Amino-1MQ) in one vial.
The mix is 10:1:1 by milligrams — almost all NAD+ by weight.
5-Amino-1MQ is already documented solo here. This page is only the branded combo.

If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.

Mechanism of action

NAD+: redox cofactor for sirtuins and PARPs. MOTS-c: mitochondrial-encoded peptide, AMPK-linked metabolic models. 5-Amino-1MQ: NNMT inhibition that can spare NAD+ in fat-cell research. Three different chemistries, one cake.

Possible side effects / caveats

NAD+ flush or tightness, unknown 5-Amino-1MQ human dose window, MOTS-c still early in people. Fixed ratio again.

Protocol ranges

Source tier	Amount	Frequency / duration	Notes
Common vendor vial	100 mg NAD+ + 10 mg MOTS-c + 10 mg 5-Amino-1MQ	120 mg total	Confirm COA
Cited chatter	Daily mixed draw in secondary blogs	Often multi-week	Not a label
See also	NAD+, MOTS-c, 5-Amino-1MQ		Solo pages

Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.